Sugi Predict

Sugi Predict / Compounds / SCHEMBL2152137

SCHEMBL2152137

SCHEMBL2152137

CC(C)(CCO)C(=O)OCc1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 5/20 0.53
▸ KMT2A Q03164 2/20 0.47
▸ TDP1 Q9NUW8 2/20 0.47
▸ MAPK1 P28482 1/20 0.47
▸ L3MBTL1 Q9Y468 1/20 0.47
▸ SLC6A2 P23975 1/20 0.47
▸ SLC6A3 Q01959 1/20 0.47
▸ LMNA P02545 2/20 0.45
▸ HCAR2 Q8TDS4 1/20 0.44
▸ SMN1; SMN2 Q16637 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ HTR2C P28335 1/20 0.42
▸ PRKCA P17252 1/20 0.42
▸ PRKCD Q05655 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ HPGD P15428 1/20 0.42
▸ CA12 O43570 1/20 0.42
▸ AKR1B10 O60218 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1273294 0.90 CYP4F2 (0.53) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL6393090 0.87 ALDH1A1 (0.53) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL621696 0.86 ALDH1A1 (0.56) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL25576433 0.85 ALDH1A1 (0.51) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL20564956 0.85 ALDH1A1 (0.51) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
Hydrochloric Acid SCHEMBL25212066 0.84 ALDH1A1 (0.50) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL4102278 0.84 ALDH1A1 (0.50) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL22812898 0.84 ALDH1A1 (0.52) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL3280044 0.84 ALDH1A1 (0.50) ALDH1A1KMT2ATDP1MAPK1L3MBTL1
SCHEMBL28371759 0.83 ALDH1A1 (0.56) ALDH1A1KMT2ATDP1MAPK1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119285572-A Kinase inhibitors and uses thereof 戴纳立制药公司 2025-01-10 — — CN disclosed
US-20250011338-A1 Kinase Inhibitors and Uses Thereof DENALI THERAPEUTICS INC. (US) 2025-01-09 — — US disclosed
CN-119264073-A Kinase inhibitors and uses thereof 戴纳立制药公司 2025-01-07 — — CN disclosed
US-12129263-B2 Kinase inhibitors and uses thereof DENALI THERAPEUTICS INC. (US) 2024-10-29 — — US disclosed
CN-110913858-B Kinase inhibitors and uses thereof 戴纳立制药公司 2024-09-24 — — CN disclosed
US-20220041620-A1 Kinase Inhibitors and Uses Thereof DENALI THERAPEUTICS INC. (US) 2022-02-10 — — US disclosed
US-11203600-B2 Kinase inhibitors and uses thereof DENALI THERAPEUTICS INC. (US) 2021-12-21 — — US disclosed
US-11203600-B2 Kinase inhibitors and uses thereof DENALI THERAPEUTICS INC. (US) 2021-12-21 — — US disclosed
EP-3150578-B1 NOVEL PYRROLIDINE COMPOUND AND APPLICATION AS MELANOCORTIN RECEPTOR AGONIST MITSUBISHI TANABE PHARMA CORP (JP) 2020-10-14 — — EP disclosed
EP-3624797-A1 KINASE INHIBITORS AND USES THEREOF Denali Therapeutics Inc. (US) 2020-03-25 — — EP disclosed
WO-2012081736-A1 CONTINUOUS ARYCYCLIC COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-06-21 — — WO disclosed
WO-2011098398-A1 SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2011-08-18 — — WO disclosed
EP-2340021-A1 SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES F. Hoffmann-La Roche AG (CH) 2011-07-06 — — EP disclosed
US-20100152190-A1 Substituted Pyrrolidine-2-Carboxamides F. HOFFMANN-LA ROCHE AG (CH) 2010-06-17 — — US disclosed
WO-2010031713-A1 SUBSTITUTED PYRROLIDINE-2-CARBOXAMIDES F. HOFFMANN-LA ROCHE AG (CH) 2010-03-25 — — WO disclosed
US-20100075948-A1 Substituted Pyrrolidine-2-Carboxamides DING QINGJIE 2010-03-25 — — US disclosed
US-5750550-A RESPIRATORY SYSTEM DISORDERS SANOFI (FR) 1998-05-12 — — US disclosed
WO-1997010243-A1 2-(PYRAZOL-5-YL-OXYMETHYL)-1,2-BENZISOTHIAZOL-3(2H)-ONE 1,1-DIOXIDES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM SANOFI (US) 1997-03-20 — — WO disclosed
US-4732902-A ENANTIOMORPHS AND CHEMICAL INTERMEDIATES HOFFMANN-LA ROCHE INC. (US) 1988-03-22 — — US disclosed
EP-0246529-A2 Long acting pyrrolo (2,3-g) isoquinolin-4-one derivatives F. HOFFMANN-LA ROCHE AG (CH) 1987-11-25 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250011338-A1 Kinase Inhibitors and Uses Thereof MAP3K20, MAP3K6, MAP3K19 ALDH1A1 4295/4885KMT2A 1686/4885TDP1 829/4885
US-20100152190-A1 Substituted Pyrrolidine-2-Carboxamides ARG2, CCNY, PYCR1 ALDH1A1 2027/4885KMT2A 703/4885TDP1 1575/4885
US-11203600-B2 Kinase inhibitors and uses thereof MAP3K20, MAP3K6, MAP3K19 ALDH1A1 4295/4885KMT2A 1686/4885TDP1 829/4885
US-20220041620-A1 Kinase Inhibitors and Uses Thereof MAP3K20, MAP3K6, MAP3K19 ALDH1A1 4295/4885KMT2A 1686/4885TDP1 829/4885
US-20100075948-A1 Substituted Pyrrolidine-2-Carboxamides ARG2, CCNY, PYCR1 ALDH1A1 2027/4885KMT2A 703/4885TDP1 1575/4885
US-12129263-B2 Kinase inhibitors and uses thereof MAP3K20, MAP3K6, MAP3K19 ALDH1A1 4295/4885KMT2A 1686/4885TDP1 829/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.